Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. reports developments as a clinical-stage biotechnology company advancing non-viral DNA technologies for immunotherapy and vaccines. Its lead candidate, IMNN-001, is a DNA-based interleukin-12 immunotherapy being developed for localized treatment of newly diagnosed advanced ovarian cancer through the OVATION clinical program.
Company news commonly covers clinical data from OVATION studies, Phase 3 development activity, financial results and business updates, and portfolio work around the TheraPlas platform for cytokine and therapeutic-protein delivery and the PlaCCine platform for viral-antigen delivery. Updates also include capital discipline, organization changes, and presentations of translational or proof-of-concept data.
Imunon (NASDAQ: IMNN) announced CEO Dr. Corinne Le Goff will present at the Chardan 6th Annual Genetic Medicines Conference on October 3-4, 2022, in New York City. Dr. Le Goff's presentation is scheduled for October 3 at 2:30 PM ET, and it will be available live and on-demand. Imunon is a clinical-stage biotechnology company developing innovative treatments using its two platforms: TheraPlas for immunotherapies and PLACCINE for nucleic acid vaccines. The company is focused on addressing advanced ovarian cancer with its lead program, GEN-1.